eFIGURES eFigure: Standardised differences between TNF-α inhibitor users and non-users before and after matching on fixed factors and propensity scores. eTABLES eTable 1: All diagnoses of infections with related ICD 10-codes included as any serious infection with the subdivision into six site-specific groups. eTable 5. Characteristics of cohort patients with inflammatory bowel disease treated with TNF-α inhibitors and azathioprine as monotherapy, before and after matching on propensity scores. eTable 6: Array approach testing the impact of unmeasured confounding eTable 7. Hazard ratios for any serious infection comparing current and past TNF-α inhibitor users with non-users based on a propensity score matched sub-cohort. eTable 8: Hazard ratios for any serious infection comparing TNF-α inhibitor users and non-users not matched on propensity scores, within a 90 days and 365 days risk period and according to sex and inflammatory bowel disease subtype. eTable 9. Characteristics of 1) TNF-α inhibitor users before propensity score matching, 2) TNF-α inhibitor users included in the propensity score matched cohort and, 3) TNF-α inhibitor users excluded from the propensity score matched cohort. eFigure 1. Standardised differences between TNF-α inhibitor users and non-users before and after matching on fixed factors and propensity scores.
eTable 1: All diagnoses of infections with related ICD 10-codes included as any serious infection with the subdivision into six site-specific groups.
Subgroup of infection Diagnoses ICD-10
Respiratory tract infections Mastoiditis H70 Nasopharyngitis A36.1 Sinuitis J01.0-J01.9 Pharyngitis J02.0-J02.9 Tonsillitis A36.0; J03.0-J03.9 Laryngitis and tracheitis A36.2; J04.0-J05.9; J37.0-J37.9 Acute upper respiratory infections of multiple and unspecified sites A36.8-A36.9; J06.0-J06.9
Abscessus peritonsillaris J36.0-J36.9 Pneumonia A48.1; B01.2; J12.0-J18.9; J10.0 Other acute lower respiratory infections A37.0-A37.9; A42.0; J20.0-J22.9 Abscessus pulmonis J85 Empyema pleurae J86
Infections of the gastrointestinal tract a
Intestinal infectious disease A00.0-A09.9 (but not A02. 
Other infections
Infection of the eye B30; H00.0; H03.0-H03.1; H06.1; H10.0; H10.5-H10.8 Infections of the musculoskeletal system and connective tissue M00.0-M01.9; M60.0; M86.0-M86.9
Infections in the nervous system G00-G01; A39.0; A32.1; A87; B00.3-4; B01.0; B02.1; B05.1; B06.0; A83; G04.0-G05.9; G02; G06 Certain bacterial disease A20.0-A29.9; A32.0-A.32.9 A.34.0-A35.9 ; A38.0; A42.2-A44.9; A48.0; A48.2-A49.9; A15-A19; A31; Spirochaetal disease A65.0-A69.9 Rickettsiosis A75.0-A79.9 Viral infections A80.0-A99.9; B05.0-B06.9; B08.1-B09.9; B26-B27; B33.0-B34.9; B25; Mycoses B37.0-B49.9; B59 Protozoal diseases B50.0-B83.9; A07.2; Unspecified infectious diseases B99.9 a Anorectal and intestinal abscess were excluded as such a diagnosis is most probably due to IBD and not the therapy. Abbreviations: ICD, international classification of disease. Not included in the propensity score eTable 3. Characteristics of TNF-α inhibitor users and non-users before* matching on propensity scores. Abbreviations: 5-ASA, 5-aminosalicylic acid; IBD, inflammatory bowel disease; SD, standard deviation; TNF, tumour necrosis factor.
All characteristics are as current at cohort entry unless stated otherwise.
*Not matched on propensity scores but matched on fixed factors including sex, age, disease duration and IBD subtype.
eTable 4. Characterisation of the distribution of the serious infection cases observed in TNF-α inhibitor users and non-users within 365 days of treatment initiation. (43) 2441 (44) 116 (43) 116 (43) IBD subtype
Number of infections in TNF-α inhibitor users

Number of infections in TNF-α inhibitor non-users
Crohn's disease 508 (42) 2566 (46) 144 (54) 144 (54) Ulcerative colitis 703 (58) 2979 (54) 124 (46) 124 (46) Disease duration, years <1 499 (41) 2709 (49) 154 (58) 153 (57) 1-4 285 (24) 1528 (28) 69 (26) 71 (27) 5-9 197 (16) 763 (14) 20 (8) 19 (7) 10-19 213 (18) 515 (9) 25 (9) 25 (9) ≥20 17 (1) 30 (1) 0 0
Place of birth
Denmark 1155 (95) 5274 (95) 263 (98) 257 (96) Europe 23 (2) 107 (2) 2 (1) 
Gastrointestinal
Intestinal surgery 132 (11) 551 (10) 30 (11) 25 (9) Intestinal-/anal-/rectal fissure/fistula/abscess 96 (8) 255 (5) 29 (11) 14 (5) Cardiovascular disease 83 (7) 318 (6) 13 (5) (17) 670 (12) 35 (13) 47 (18) Pulmonary antiobstructive 104 (9) 556 (10) 14 (5) 25 (9) Antimicrobials 598 (49) 2470 (45) 118 (44) 123 (46) Prescription drugs used in last 6 months, No. 0 68 (6) 3829 (69) 59 (22) 59 (22) 1-2 163 (14) 168 (3) 18 (7) 21 (8) 3-4 192 (16) 247 (5) 36 (13) 36 (13) ≥5 788 (65) 1301 (24) 155 (58) 152 (57) IBD drugs a 5-ASA/sulfasalazine 632 (52) 3514 (63) 132 (49) 151 (56) Intestinal corticosteroids 332 (27) 2159 (39) 85 (32) 89 (33) Methotrexate/Cyclosporine/Cyclophosphamide 105 (9) 40 (1) 3 (1) 2 (1) Oral corticosteroids 606 (50) 3794 (68) 138 (52) 199 ( (68) 180 (67) 187 (70) ≥3 249 (21) 849 (15) 54 (20) 46 (17) Abbreviations: 5-ASA, 5-aminosalicylic acid; IBD, inflammatory bowel disease; SD, standard deviation; TNF, tumour necrosis factor.
*Not matched on propensity scores but matched on fixed factors including sex, age, disease duration and IBD subtype. Pharmacoepidemiol Drug Safety, 2006; 15:291-303. 
